Exosome Treatments: What the Evidence Really Shows

Exosomes have become one of the most talked-about "regenerative" treatments in aesthetics, and one of the questions I hear most often from patients. Social media presents them as stem cell power in a vial. Here is how I look at the topic as a dermatologist: what exosomes actually are, what the evidence shows today, and why I am not in a hurry.

What are exosomes?

Exosomes are extracellular vesicles of roughly 30 to 150 nanometres, released by cells. They carry proteins, lipids and nucleic acids, and they take part in communication between cells. That mechanism makes them biologically plausible for skin and hair follicle regeneration. The idea itself is not unreasonable. The problem is not the idea but how it has been turned into products.

What is being promised?

Products said to contain exosomes are marketed for skin rejuvenation, acne scars, hair loss, pigmentation and wound healing all at once. They are usually applied after microneedling, fractional laser or mesotherapy. In medicine, a single product promising that many unrelated indications is always the first warning sign.

What does the evidence actually show?

Most published studies are small, weakly controlled and short in follow-up. More importantly, the products used in those studies differ from one another in cell source, concentration, purity and manufacturing method. A result obtained with one preparation cannot be transferred to another. Without standardisation there is no single scientific answer to "do exosomes work", because there is no single exosome treatment.

Approval and regulation

As of today no exosome product has been approved for any dermatologic or aesthetic use. The FDA treats products derived from human cells or tissue that claim to treat a condition as unapproved drugs or biologics, regardless of how they are marketed. Even topical application of exosomes after microneedling is considered systemic administration rather than cosmetic use.

Safety is the real issue

Serious adverse events have been documented, including severe infections and allergic reactions after clinic-administered products. Where sterile manufacturing, batch traceability and cold chain are not supervised, nobody can guarantee what is actually being delivered into the skin. For a physician this question comes before any discussion of efficacy.

What I do instead

I do not offer exosome treatments. I plan the options whose evidence and regulatory status are clear, based on the problem the patient came with: polynucleotide and skin booster treatments for skin quality, RF microneedling and fractional laser for acne scars, focused ultrasound or monopolar radiofrequency for laxity, appropriate laser and medical protocols for pigmentation, and trichoscopic assessment before any hair loss treatment. Which one fits is decided after examination and skin analysis.

This does not mean exosomes will never work. Research continues, and standardised, supervised products may appear in the coming years. But the data we have today is not enough to recommend them routinely to a patient.

Five questions to ask if exosomes are offered to you

1. What is the cell source of the product and who manufactures it?

2. Can the product's regulatory status be documented?

3. Will it be applied by breaking the skin barrier, and is the product actually approved for that use?

4. Is the person performing the procedure a physician, and in which specialty?

5. Is there an alternative with stronger evidence for the same problem?

In short

Exosomes are mechanistically interesting but neither the evidence nor the oversight is mature. The right approach today is to make the diagnosis first and solve the problem with methods whose evidence is known. Base a decision about your skin on an examination, not on a social media trend.